Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Community Acquired Bacterial Pneumonia (CABP) Treatment Market Snapshot (2023 to 2033)

The global community acquired bacterial pneumonia (CABP) treatment market is expected to garner a market value of US$ 5 billion in 2023 and is expected to accumulate a market value of US$ 8.38 billion by registering a CAGR of 5.3% in the forecast period 2023 to 2033. The market for community acquired bacterial pneumonia (CABP) treatment registered a CAGR of 3.2% in the historical period 2018 to 2022.

The market for community acquired bacterial pneumonia (CABP) treatment is expected to experience steady growth in the coming years, driven by several factors. CABP is a type of pneumonia that is acquired outside of a hospital or healthcare setting and is caused by bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Legionella pneumophila.

The global CABP treatment market includes a variety of drugs such as macrolides, fluoroquinolones, tetracyclines, and cephalosporins, which are used to treat bacterial infections. The market is expected to be driven by an increase in the incidence of CABP, an aging population, and the development of new and innovative drugs to treat the condition.

Report Attribute Details
Expected Market Value (2023) US$ 5 Billion
Anticipated Forecast Value (2033) US$ 8.38 Billion
Projected Growth Rate (2023 to 2033) 5.3% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Community Acquired Bacterial Pneumonia (CABP) Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for community acquired bacterial pneumonia (CABP) treatment reflected a value of 3.2% during the historical period, 2018 to 2022. The incidence of CABP is increasing globally, driven by factors such as smoking, chronic obstructive pulmonary disease (COPD), and an aging population. This has led to an increase in demand for CABP treatment, driving the growth of the market.

Key players in the market are focused on developing new and innovative drugs to treat CABP, which is expected to drive the growth of the market. The availability of effective antibiotics is also expected to contribute to the growth of the market. Furthermore, Increasing healthcare spending in developing countries is expected to drive the growth of the market in these regions. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, driven by the large population and increasing healthcare spending in countries such as India and China.

Overall, the market for community acquired bacterial pneumonia (CABP) treatment is expected to register a CAGR of 5.3% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Community Acquired Bacterial Pneumonia (CABP) Treatment Market?

Increasing Prevalence of Community Acquired Bacterial Pneumonia (CABP) to push market growth

An increase in the incidence of Community Acquired Bacterial Pneumonia (CABP) is expected to drive the growth of the CABP treatment market. CABP is a common type of pneumonia that is acquired outside of a hospital or healthcare setting and is caused by bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Legionella pneumophila.

The incidence of CABP is increasing globally due to factors such as smoking, chronic obstructive pulmonary disease (COPD), and an aging population. According to studies, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In addition to this, approximately 650 adults are hospitalized with CAP every year per 100,000 population in the United States, corresponding to 1.5 million unique CAP hospitalizations each year. As the incidence of CABP increases, the demand for CABP treatment is also expected to increase, which is likely to drive the growth of the market.

Moreover, the availability of effective antibiotics and the development of new and innovative drugs to treat CABP are also expected to contribute to the growth of the market.

In addition to these factors, increasing healthcare spending in developing countries and the presence of advanced healthcare infrastructure in developed regions are also expected to drive the growth of the CABP treatment market. Overall, the CABP treatment market is expected to experience steady growth in the coming years, driven by an increase in the incidence of CABP and other factors.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by Community Acquired Bacterial Pneumonia (CABP) Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The cost of treatment for community acquired bacterial pneumonia (CABP) can be high, particularly for advanced cases that require more invasive procedures. This can make it difficult for some patients to afford treatment, which can limit market growth.

Additionally, despite increasing awareness of Community Acquired Bacterial Pneumonia (CABP), there is still a lack of knowledge and understanding about the condition among the general population. This can lead to delays in diagnosis and treatment, which can impact the growth of the market.

Moreover, the regulatory requirements for approval of new treatments for Community Acquired Bacterial Pneumonia (CABP) can be stringent, which can limit the number of treatments that make it to market. This can impact the availability of new and innovative treatments for patients.

Region-Wise Insights

How is the Community Acquired Bacterial Pneumonia (CABP) Treatment Market Turning Out in the South & East Asia Region?

Increasing awareness and diagnosis of the condition Shaping Landscape for CABP Treatment in South & East Asia

The South and East Asia region is a growing market for community acquired bacterial pneumonia (CABP) treatment. The region includes countries such as India, China, Japan, South Korea, and the ASEAN countries. The market is driven by the increasing prevalence of CABP and the growing demand for effective treatments in the region.

This growth can be attributed to factors such as the increasing aging population, high burden of respiratory diseases, and increasing healthcare spending in countries such as India and China.

In India, the prevalence of CABP is high, especially among the elderly and immunocompromised populations. The market is witnessing the entry of new players, including local and international pharmaceutical companies, which is expected to increase competition and innovation in the market.

In China, the prevalence of CABP is also high, driven by factors such as air pollution, smoking, and an aging population. The government is taking steps to improve healthcare infrastructure and increase access to healthcare services, which is expected to drive the growth of the market.

Overall, the CABP treatment market in the South and East Asia region is turning out to be a promising market with significant growth potential. The increasing prevalence of CABP and the growing demand for effective treatments are expected to drive the growth of the market in the region in the coming years.

What are the Factors Boosting the Market for Community Acquired Bacterial Pneumonia (CABP) Treatment in North America?

Increasing Focus on Technological Advancements Shaping Landscape for CABP Treatment in North America

The incidence of CABP is high in North America, particularly in the elderly and immunocompromised populations. This has led to a high demand for effective CABP treatments in the region. North America has a significant pipeline of new antibiotics under development for the treatment of CABP. This has led to the availability of new and effective treatments, which is expected to drive the growth of the market.

Furthermore, North America has a strong healthcare infrastructure, with well-trained healthcare providers and access to advanced medical technologies. This has helped to support the development and adoption of new treatments for Community Acquired Bacterial Pneumonia (CABP).

Overall, these factors are driving the growth of the Community Acquired Bacterial Pneumonia (CABP) Treatment market in North America. However, there are still challenges facing the market, including high treatment costs and the need for more effective and targeted therapies. Nonetheless, the market is expected to continue growing as new treatments and technologies are developed and as the awareness of community acquired bacterial pneumonia (CABP) continues to increase.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Route of Administration, Which Segment is Likely to Account for a Significant Share?

Intravenous (IV) route of administration to hold a significant share and push market growth

Among the different treatments for community acquired bacterial pneumonia (CABP), the intravenous (IV) route of administration is likely to account for a significant share of the market.

This is because IV antibiotics are often the first-line treatment for severe cases of CABP, where prompt and effective treatment is critical for improving patient outcomes. IV antibiotics can rapidly achieve therapeutic levels in the bloodstream, leading to a faster resolution of symptoms and a shorter hospital stay.

Additionally, IV antibiotics can be administered in a hospital or outpatient setting, depending on the severity of the illness, which adds to the convenience of treatment for patients.

Overall, while the IV route of administration is likely to account for a significant share of the CABP treatment market, the inhaled route of administration is an emerging segment that is expected to gain traction in the coming years.

By Distribution Channel, Which Segment is Likely to Account for a Significant Share?

Hospital pharmacies segment to hold a significant share and push market growth

Hospital pharmacies play a critical role in the management of CABP, as they are often the first point of contact for patients with CABP. Hospital pharmacies provide access to a wide range of medications and specialized treatment options, including invasive procedures and advanced imaging techniques, which are essential for the management of CABP.

In addition, hospital pharmacies have access to a multidisciplinary team of healthcare professionals, including physicians, nurses, and pharmacists, who can collaborate to provide comprehensive care to patients with CABP. This team-based approach is critical for the management of CABP, as it allows for individualized treatment plans that address the unique needs of each patient

Market Competition

Key players in the market include companies such as Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix along with healthcare providers and technology companies among other global players.

  • The USA Food and Drug Administration granted approval for Xenleta (lefamulin) to treat adults suffering from community-acquired bacterial pneumonia. This new drug provides an additional treatment option for patients with this serious illness, which can range in severity from mild to severe and affect people of all ages.
  • According to the Centers for Disease Control and Prevention, about one million people in the United States are hospitalized with community-acquired pneumonia each year, and approximately 50,000 individuals succumb to the disease. Dr. Ed Cox, Director of FDA’s Office of Antimicrobial Products, stated that the approval of Xenleta is a significant step in facilitating the development of new antibiotics and addressing the treatment of infectious diseases.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 5 billion
Market Value in 2033 US$ 8.38 billion
Growth Rate CAGR of 5.3% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Route of Administration
  • Dose Form
  • Drug Class
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Nabriva Therapeutics
  • Melinta Therapeutics
  • Wakunaga Pharmaceutical Co. Ltd.
  • Actavis Generics
  • Pfizer Inc.
  • Paratek Pharmaceuticals
  • Cumberland Pharmaceuticals Inc.
  • Theravance Biopharma Inc.
  • Merck Sharp & Dohme Inc.
  • Cubist Pharmaceuticals LLC (Merck)
  • Shionogi Inc.
  • Allergan Plc.
  • Eagle Pharmaceuticals Inc.
  • Combioxin
  • TiGenix
Customization Available Upon Request

Key Segments Profiled in the Community Acquired Bacterial Pneumonia (CABP) Treatment Industry Survey

Dose Form:

  • Solution
  • Tablet

Drug Class:

  • Pleuromutilin
  • Cephalosporin
  • Glycylcycline
  • Oxazolidinone
  • Ketolide

Route of Administration:

  • Oral
  • Intravenous

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Current Market Size of CABP?

In 2023, the market may potentially be worth US$ 5 billion.

What is the Estimated Market Growth From 2023 to 2033?

The market may steadily transform at a CAGR of 5.3% through 2033.

How was the Past Performance of the Market?

The market registered a HCAGR of 3.2 between 2018 and 2022.

What will the Market Size of CABP in 2033?

The estimated value of the global market in 2033 is US$ 8.38 billion.

Which Distribution Channel Segment is Forecast to Hold a Strong Share?

Hospital pharmacies are poised to capture a considerable market share.

Table of Content

1. Executive Summary | Community Acquired Bacterial Pneumonia (CABP) Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Pleuromutilin

        5.3.2. Cephalosporin

        5.3.3. Glycylcycline

        5.3.4. Oxazolidinone

        5.3.5. Ketolide

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dose Form

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Dose Form, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dose Form, 2023 to 2033

        6.3.1. Solution

        6.3.2. Tablet

    6.4. Y-o-Y Growth Trend Analysis By Dose Form, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Dose Form, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        7.3.1. Oral

        7.3.2. Intravenous

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. Middle East & Africa

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Drug Class

        10.2.3. By Dose Form

        10.2.4. By Route of Administration

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Dose Form

        10.3.4. By Route of Administration

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Class

        11.2.3. By Dose Form

        11.2.4. By Route of Administration

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Dose Form

        11.3.4. By Route of Administration

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. United kingdom

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug Class

        12.2.3. By Dose Form

        12.2.4. By Route of Administration

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Dose Form

        12.3.4. By Route of Administration

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Drug Class

        13.2.3. By Dose Form

        13.2.4. By Route of Administration

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Dose Form

        13.3.4. By Route of Administration

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Class

        14.2.3. By Dose Form

        14.2.4. By Route of Administration

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Dose Form

        14.3.4. By Route of Administration

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Drug Class

        15.2.3. By Dose Form

        15.2.4. By Route of Administration

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Dose Form

        15.3.4. By Route of Administration

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Drug Class

        16.2.3. By Dose Form

        16.2.4. By Route of Administration

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug Class

        16.3.3. By Dose Form

        16.3.4. By Route of Administration

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Drug Class

            17.1.2.2. By Dose Form

            17.1.2.3. By Route of Administration

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Drug Class

            17.2.2.2. By Dose Form

            17.2.2.3. By Route of Administration

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Drug Class

            17.3.2.2. By Dose Form

            17.3.2.3. By Route of Administration

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Drug Class

            17.4.2.2. By Dose Form

            17.4.2.3. By Route of Administration

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Drug Class

            17.5.2.2. By Dose Form

            17.5.2.3. By Route of Administration

            17.5.2.4. By Distribution Channel

    17.6. United kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Drug Class

            17.6.2.2. By Dose Form

            17.6.2.3. By Route of Administration

            17.6.2.4. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Drug Class

            17.7.2.2. By Dose Form

            17.7.2.3. By Route of Administration

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Drug Class

            17.8.2.2. By Dose Form

            17.8.2.3. By Route of Administration

            17.8.2.4. By Distribution Channel

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Drug Class

            17.9.2.2. By Dose Form

            17.9.2.3. By Route of Administration

            17.9.2.4. By Distribution Channel

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Drug Class

            17.10.2.2. By Dose Form

            17.10.2.3. By Route of Administration

            17.10.2.4. By Distribution Channel

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Drug Class

            17.11.2.2. By Dose Form

            17.11.2.3. By Route of Administration

            17.11.2.4. By Distribution Channel

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Drug Class

            17.12.2.2. By Dose Form

            17.12.2.3. By Route of Administration

            17.12.2.4. By Distribution Channel

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Drug Class

            17.13.2.2. By Dose Form

            17.13.2.3. By Route of Administration

            17.13.2.4. By Distribution Channel

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Drug Class

            17.14.2.2. By Dose Form

            17.14.2.3. By Route of Administration

            17.14.2.4. By Distribution Channel

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Drug Class

            17.15.2.2. By Dose Form

            17.15.2.3. By Route of Administration

            17.15.2.4. By Distribution Channel

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Drug Class

            17.16.2.2. By Dose Form

            17.16.2.3. By Route of Administration

            17.16.2.4. By Distribution Channel

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Drug Class

            17.17.2.2. By Dose Form

            17.17.2.3. By Route of Administration

            17.17.2.4. By Distribution Channel

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Drug Class

            17.18.2.2. By Dose Form

            17.18.2.3. By Route of Administration

            17.18.2.4. By Distribution Channel

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Drug Class

            17.19.2.2. By Dose Form

            17.19.2.3. By Route of Administration

            17.19.2.4. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Drug Class

            17.20.2.2. By Dose Form

            17.20.2.3. By Route of Administration

            17.20.2.4. By Distribution Channel

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Drug Class

            17.21.2.2. By Dose Form

            17.21.2.3. By Route of Administration

            17.21.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Drug Class

        18.3.3. By Dose Form

        18.3.4. By Route of Administration

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Nabriva Therapeutics

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Melinta Therapeutics

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Wakunaga Pharmaceutical Co. Ltd.

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Actavis Generics

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Pfizer

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Paratek Pharmaceuticals

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Cumberland Pharmaceuticals Inc.

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Theravance Biopharma Inc.

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Merck Sharp & Dohme Inc.

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Cubist Pharmaceuticals LLC (Merck)

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Shionogi Inc.

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

        19.1.12. Allergan Plc. 

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

        19.1.13. Eagle Pharmaceutical Inc.

            19.1.13.1. Overview

            19.1.13.2. Product Portfolio

            19.1.13.3. Profitability by Market Segments

            19.1.13.4. Sales Footprint

            19.1.13.5. Strategy Overview

                19.1.13.5.1. Marketing Strategy

        19.1.14. Combioxin

            19.1.14.1. Overview

            19.1.14.2. Product Portfolio

            19.1.14.3. Profitability by Market Segments

            19.1.14.4. Sales Footprint

            19.1.14.5. Strategy Overview

                19.1.14.5.1. Marketing Strategy

        19.1.15. Takeda

            19.1.15.1. Overview

            19.1.15.2. Product Portfolio

            19.1.15.3. Profitability by Market Segments

            19.1.15.4. Sales Footprint

            19.1.15.5. Strategy Overview

                19.1.15.5.1. Marketing Strategy

        19.1.16. TiGenix

            19.1.16.1. Overview

            19.1.16.2. Product Portfolio

            19.1.16.3. Profitability by Market Segments

            19.1.16.4. Sales Footprint

            19.1.16.5. Strategy Overview

                19.1.16.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Bacterial Diagnostics in Aquaculture Market

Published : August 2023

Healthcare

Antibacterial Haemostatic Gels Market

Published : April 2023

Healthcare

Bronchitis Treatment Market

Published : November 2022

Healthcare

Pneumonia Diagnostics Market

Published : October 2022

Explore Healthcare Insights

View Reports

Community Acquired Bacterial Pneumonia (CABP) Treatment Market